title: Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine.
abstract: Antibody decay after a single dose of acellular pertussis vaccine containing 25 microg of pertussis toxin (PT), 25 microg of filamentous hemagglutin (FHA), and traces of pertactin (PRN) was monitored in health-care workers. Blood was sampled 4 weeks (n = 246), 1 year (n = 187), 2 years (n = 53), 3 years (n = 134), and 4 years (n = 37) after vaccination. IgG anti-PT, IgG anti-FHA and IgG anti-PRN were measured by ELISA. Peak median antibodies to PT, FHA, and PRN were 314, 785, and 84 EU/ml respectively. IgG anti-PT decreased to a median of 29% (76 EU/ml), 18% (64 EU/ml), 19% (58 EU/ml), and 20% (63 EU/ml) of the peak value after 1, 2, 3, and 4 years respectively. IgG anti-FHA decreased more slowly, but showed similar decay patterns. In German health-care workers antibodies to pertussis antigens decayed rapidly within the first year after vaccination, but remained stable after 2, 3, and 4 years. This observation may have implications for the timing of booster vaccinations in adults.
authors.affiliation: Institut für Infektiologie Krefeld, Krefeld, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Riffelmann
authors.forename: M
authors.initials: M
authors.lastname: Littmann
authors.forename: C
authors.initials: C
authors.lastname: Hülsse
authors.forename: C H Wirsing
authors.initials: CH
authors.lastname: von König
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005858:Germany; D006282:Health Personnel; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008137:Longitudinal Studies; D008875:Middle Aged; D010567:Pertussis Vaccine / Q000276:immunology*; D022282:Vaccines, Acellular / Q000276:immunology; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular
references.citation: Pediatr Infect Dis J. 2000 Aug;19(8):757-9
references.pmid: 10959748
references.citation: Vaccine. 2007 Nov 23;25(48):8172-9
references.pmid: 17945400
references.citation: Clin Infect Dis. 2007 May 15;44(10):1271-7
references.pmid: 17443462
references.citation: N Engl J Med. 2007 Jan 11;356(2):110-3
references.pmid: 17215528
references.citation: J Infect Dis. 1996 Nov;174 Suppl 3:S281-6
references.pmid: 8896530
references.citation: Vaccine. 2004 Dec 2;23(3):380-5
references.pmid: 15530684
references.citation: Clin Microbiol Rev. 2008 Jul;21(3):426-34
references.pmid: 18625679
references.citation: Clin Infect Dis. 2001 Oct 1;33(7):997-1003
references.pmid: 11528571
references.citation: Clin Infect Dis. 2008 Aug 1;47(3):401-9
references.pmid: 18558875
references.citation: J Infect Dis. 2004 Aug 1;190(3):535-44
references.pmid: 15243929
references.citation: MMWR Recomm Rep. 2006 Dec 15;55(RR-17):1-37
references.pmid: 17167397
references.citation: Clin Infect Dis. 2004 Jul 15;39(2):179-85
references.pmid: 15307026
references.citation: Eur J Clin Microbiol Infect Dis. 1999 May;18(5):341-5
references.pmid: 10421041
references.citation: Z Arztl Fortbild (Jena). 1989;83(6):309-12
references.pmid: 2660433